Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood mutation may reveal hidden lymphoma after treatment

NCT ID NCT02815137

Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 137 adults with newly diagnosed classical Hodgkin lymphoma to see if a specific genetic change (XPO1 E571K) found in their blood could signal whether cancer remains after chemotherapy. Researchers compared the blood test results with standard PET scans to measure how well the mutation detects leftover disease. The goal is to find a simpler, less expensive way to monitor treatment success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

137 people

The number who actually took part.

Started

Jun 2016

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Pathologically confirmed, recent diagnosis of classical Hodgkin Lymphoma * treatment planned with Adriamycin Bleamycin Vinblastine Dacarbazine (ABVD) or Bleomycin Etoposide Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone (BEACOPP) regimen (and radiotherapy if applicable) * all stages (Ann Arbor I - IV) * Written informed consent * Patient affiliated or beneficiary of a benefit system * untreated patient (no corticosteroids or chemotherapy) Exclusion Criteria: * No informed consent * Treatment by ABVD or BEACOPP not indicated * Previously treated Hodgkin lymphoma (including corticosteroids) * Patients who are pregnant or lactating * Active Hepatitis B or Hepatitis C infection * Known human immunodeficiency virus (HIV) infection - Patient with no social protection * Patient under tutorship or curatorship * Patient not affiliated of beneficiary of a benefit system * Medical contraindication to PET/CT

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Classical Hodgkin lymphoma

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, 76000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.